#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13536	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2723	606.1	0	.	n	.	0	A69G	SNP	69	69	A	637	637	G	847	G,A	845,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13536	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2723	606.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	2018	2018	T	844	T,G	843,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13536	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2723	606.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1752	1752	C	818	C,T,G	815,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23696	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4172	707.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1926	1926	A	934	A,T,C	932,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23696	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4172	707.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2560	2560	C	846	C,T,G,A	843,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23696	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4172	707.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2634	2634	A	831	A,T,C	827,2,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23696	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4172	707.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3186	3186	C	846	C	846	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2114	folP	852	852	99.88	folP.l15.c4.ctg.1	2008	131.3	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1023	1025	AAA	212;209;209	A;A;A,C,T	212;209;206,2,1	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2114	folP	852	852	99.88	folP.l15.c4.ctg.1	2008	131.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1254	1256	AGC	219;220;222	A;G,C,T;C	219;218,1,1;222	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5074	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3855	163.8	1	SNP	p	S91F	0	.	.	271	273	TCC	877	879	TCC	182;184;185	T,C;C;C	180,2;184;184	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5074	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3855	163.8	1	SNP	p	D95G	0	.	.	283	285	GAC	889	891	GAC	193;195;195	G;A,T,C;C	193;193,1,1;195	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5074	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3855	163.8	1	SNP	p	D95N	0	.	.	283	285	GAC	889	891	GAC	193;195;195	G;A,T,C;C	193;193,1,1;195	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1742	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1796	121.1	1	SNP	p	G45D	0	.	.	133	135	GGC	701	703	GGC	188;188;188	G;G;C	188;188;188	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1038	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1509	85.8	0	.	n	.	0	A197.	DEL	197	197	A	848	848	A	194	A	194	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4794	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3466	172.4	1	SNP	p	D86N	0	.	.	256	258	GAC	854	856	GAC	222;223;224	G,A;A,G;C	221,1;222,1;224	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4794	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3466	172.4	1	SNP	p	S87W	0	.	.	259	261	AGT	857	859	AGT	224;226;226	A,C;G,A;T	223,1;225,1;226	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4794	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3466	172.4	1	SNP	p	S87I	0	.	.	259	261	AGT	857	859	AGT	224;226;226	A,C;G,A;T	223,1;225,1;226	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4794	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3466	172.4	1	SNP	p	S87R	0	.	.	259	261	AGT	857	859	AGT	224;226;226	A,C;G,A;T	223,1;225,1;226	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4794	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3466	172.4	1	SNP	p	S88P	0	.	.	262	264	TCC	860	862	TCC	228;228;225	T,A;C;C,A,T	227,1;228;223,1,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4016	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3087	162.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1790	1792	GGC	212;210;209	G,C;G;C	211,1;210;209	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3804	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2915	162.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1491	1493	GCA	208;210;213	G;C,A,G;A	207;208,1,1;213	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3804	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2915	162.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1494	1496	ATC	215;218;222	A,G,C;T,G;C	213,1,1;217,1;222	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3804	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2915	162.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1506	1508	GTG	218;219;220	G;T,G;G,C	217;218,1;219,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3804	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2915	162.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1506	1508	GTG	218;219;220	G;T,G;G,C	217;218,1;219,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3804	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2915	162.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2010	2012	ACC	224;222;222	A;C;C,A	224;222;221,1	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3804	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2915	162.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2064	2066	GCG	206;207;204	G;C,G;G	206;206,1;204	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3804	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2915	162.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2064	2066	GCG	206;207;204	G;C,G;G	206;206,1;204	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3804	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2915	162.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2187	2189	GGC	222;223;223	G,A;G,T;C	221,1;222,1;223	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3804	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2915	162.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2196	2198	GGC	220;222;223	G,T;G;C,A,G	218,2;222;220,2,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3804	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2915	162.5	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2214	2216	CTG	211;212;212	C;T;G,T	211;212;211,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5266	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3695	177.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1927	1929	CCG	211;212;210	C;C;G	211;212;210	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2048	porA	1146	1146	99.65	porA.l6.c30.ctg.1	2488	102.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	897	897	C	145	C	145	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	18;21;23	T,G;T;A	17,1;21;23	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	50;50;50	C;A;T	50;50;50	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	50;50;50	A;G;T	50;50;50	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	50;50;50	T;A;C	50;50;50	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	378	26.0	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	97	94.85	porB1a.l15.c17.ctg.3	178	50.5	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	53;51;47	A;C;G	53;51;47	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	268	porB1a	984	97	94.85	porB1a.l15.c17.ctg.3	178	50.5	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	10;10;10	C;A;A	10;10;10	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2832	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1794	194.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	601	603	GAA	246;242;243	G;A;A	246;242;243	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2832	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1794	194.4	0	.	p	.	0	N134D	NONSYN	400	402	AAT	889	891	GAT	236;237;235	G;A;T	236;237;235	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2832	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1794	194.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1012	1014	TCA	248;248;248	T;C,G;A	248;247,1;248	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2832	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1794	194.4	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1141	1143	GTC	237;236;234	G,C;T,G;C,T,A	236,1;235,1;232,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2832	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1794	194.4	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1153	1155	TCT	230;230;229	T;C;T,C	230;230;228,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2832	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1794	194.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1471	1473	GCA	237;238;240	G;C;A,G	237;238;239,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2832	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1794	194.4	1	SNP	p	G120K	1	.	.	358	360	AAG	847	849	AAG	250;249;246	A;A;G,C	250;249;245,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2832	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1794	194.4	1	SNP	p	D121N	0	.	.	361	363	GAC	850	852	GAC	247;247;245	G;A,T;C	247;245,2;245	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2832	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1794	194.4	1	SNP	p	A121D	1	.	.	361	363	GAC	850	852	GAC	247;247;245	G;A,T;C	247;245,2;245	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9428	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5375	218.7	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2198	2200	AAT	250;251;249	A,C;A;T	248,2;251;249	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1420	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1556	113.8	1	SNP	p	V57M	1	.	.	169	171	ATG	817	819	ATG	265;268;266	A;T,A;G	265;267,1;266	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
